{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:57:38Z","timestamp":1762833458258,"version":"build-2065373602"},"reference-count":96,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T00:00:00Z","timestamp":1468972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["1120731"],"award-info":[{"award-number":["1120731"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ekir.2016.06.009","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T17:23:13Z","timestamp":1469726593000},"page":"327-339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease\u2014The Berlin Roadmap"],"prefix":"10.1016","volume":"1","author":[{"given":"Hans-Joachim","family":"Anders","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad","family":"Rovin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Brunetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish Kumar","family":"Devarapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dick","family":"de Zeeuw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Duffield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Eulberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Fierro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Frese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Guillevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Holdsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Kettritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malte","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa","family":"Lapteva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeera","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liz","family":"Lightstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Mack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ladan","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"McAdoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eoin","family":"McKinney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Panzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Pusey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaim","family":"Putterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ton","family":"Rabelink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Radbruch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Rees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlies","family":"Reinders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Sacks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J","family":"Schall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Meyer-Schwesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola M.","family":"Tomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2016.06.009_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneph.2016.18","article-title":"Biologics for the treatment of autoimmune renal diseases","volume":"12","author":"Holdsworth","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrneph.2015.206","article-title":"Hurdles to the introduction of new therapies for immune-mediated kidney diseases","volume":"12","author":"Anders","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib3","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMp1113569","article-title":"The burden of disease and the changing task of medicine","volume":"366","author":"Jones","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2016.06.009_bib4","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(15)00128-2","article-title":"Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Forouzanfar","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2016.06.009_bib5","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ki.2015.230","article-title":"A\u00a0systematic analysis of worldwide population-based data on the global burden of\u00a0chronic kidney disease in 2010","volume":"88","author":"Mills","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2016.06.009_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/ckj\/sfv111","article-title":"The global nephrology workforce: emerging threats and potential solutions!","volume":"9","author":"Sharif","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2016.06.009_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1440-1797.2007.00887.x","article-title":"How to attract a nephrology trainee: quantitative questionnaire results","volume":"13","author":"Lane","year":"2008","journal-title":"Nephrology"},{"year":"2014","author":"Salsberg","series-title":"The US Nephrology Workforce: Developments and Trends","key":"10.1016\/j.ekir.2016.06.009_bib8"},{"key":"10.1016\/j.ekir.2016.06.009_bib9","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1681\/ASN.2009121248","article-title":"The clinical importance of nephron mass","volume":"21","author":"Luyckx","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib10","article-title":"Aging and the kidneys: anatomy, physiology and consequences for defining chronic kidney disease","volume":"132","author":"Glassock","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2016.06.009_bib11","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ekir.2016.06.009_bib12","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient's care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2016.06.009_bib13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib14","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2016.06.009_bib15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/nm0909-1006","article-title":"The advancement of translational medicine-from regional challenges to global solutions","volume":"15","author":"Albani","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2016.06.009_bib16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.ajkd.2016.01.030","article-title":"Membranous nephropathy: a journey from bench to bedside","volume":"68","author":"Francis","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2016.06.009_bib17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2012.05.003","article-title":"Role of TWEAK in lupus nephritis: a bench-to-bedside review","volume":"39","author":"Michaelson","year":"2012","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.ekir.2016.06.009_bib18","doi-asserted-by":"crossref","first-page":"320ps321","DOI":"10.1126\/scitranslmed.aac9888","article-title":"Data gaps limit the translational potential\u00a0of preclinical research","volume":"8","author":"Kleiman","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ekir.2016.06.009_bib19","doi-asserted-by":"crossref","first-page":"47ps44","DOI":"10.1126\/scitranslmed.3001040","article-title":"Translational medicine and the\u00a0value of biomarker qualification","volume":"2","author":"Goodsaid","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ekir.2016.06.009_bib20","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2016.06.009_bib21","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2016.06.009_bib22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1193032","article-title":"Association of trypanolytic ApoL1 variants with kidney disease in African Americans","volume":"329","author":"Genovese","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ekir.2016.06.009_bib23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00439-010-0861-0","article-title":"Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene","volume":"128","author":"Tzur","year":"2010","journal-title":"Hum Genet"},{"key":"10.1016\/j.ekir.2016.06.009_bib24","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2015111220","article-title":"APOL1-G0 or APOL1-G2 transgenic models develop preeclampsia but not kidney disease","author":"Bruggeman","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib25","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ki.2012.428","article-title":"Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach","volume":"83","author":"Gadegbeku","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2016.06.009_bib26","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/ndt\/gfv108","article-title":"Pro: \u201cThe usefulness of biomarkers in glomerular diseases\u201d. The problem: moving from syndrome to mechanism\u2014individual patient variability in disease presentation, course and response to therapy","volume":"30","author":"Mariani","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2016.06.009_bib27","first-page":"1","article-title":"From the large scale\u00a0expression analysis of lupus nephritis to targeted molecular medicine","volume":"3","author":"Berthier","year":"2012","journal-title":"J\u00a0Data Mining Genomics Proteomics"},{"key":"10.1016\/j.ekir.2016.06.009_bib28","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/art.38220","article-title":"End-stage renal disease in African Americans with lupus nephritis is associated with APOL1","volume":"66","author":"Freedman","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2016.06.009_bib29","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ekir.2016.06.009_bib30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2016.06.009_bib31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib32","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib33","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/TP.0000000000000694","article-title":"A\u00a0Banff component scoring-based histologic assessment of bortezomib-based antibody-mediated rejection therapy","volume":"99","author":"Sadaka","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2016.06.009_bib34","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","article-title":"Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis","volume":"15","author":"Booth","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2016.06.009_bib36","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.2353\/ajpath.2010.091227","article-title":"4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice","volume":"176","author":"Kulkarni","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ekir.2016.06.009_bib37","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/0961203308089408","article-title":"Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study","volume":"17","author":"Wang","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2016.06.009_bib38","doi-asserted-by":"crossref","first-page":"e0144548","DOI":"10.1371\/journal.pone.0144548","article-title":"The efficacy and safety of leflunomide for the treatment of lupus nephritis in Chinese patients: systematic review and meta-analysis","volume":"10","author":"Cao","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2016.06.009_bib39","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1002\/art.38665","article-title":"Low-dose irinotecan improves advanced lupus nephritis in mice potentially by changing DNA relaxation and anti-double-stranded DNA binding","volume":"66","author":"Frese-Schaper","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2016.06.009_bib40","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-pathol-011110-130230","article-title":"Mesenchymal stem cells: mechanisms of inflammation","volume":"6","author":"Singer","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.ekir.2016.06.009_bib41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrneph.2016.7","article-title":"Mesenchymal stromal cells in renal transplantation: opportunities and challenges","volume":"12","author":"Casiraghi","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11892-016-0734-6","article-title":"The promise of mesenchymal stem cell therapy for diabetic kidney disease","volume":"16","author":"Griffin","year":"2016","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.ekir.2016.06.009_bib43","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/eji.201444971","article-title":"B-cell inhibition by cross-linking CD79b is superior to B-cell depletion with anti-CD20 antibodies in treating murine collagen-induced arthritis","volume":"45","author":"Br\u00fchl","year":"2015","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ekir.2016.06.009_bib44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0961203312465781","article-title":"Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE","volume":"22","author":"Dooley","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2016.06.009_bib45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaut.2014.11.007","article-title":"Macrophage depletion ameliorates nephritis induced by pathogenic antibodies","volume":"57","author":"Chalmers","year":"2015","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.ekir.2016.06.009_bib46","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nm0602-582","article-title":"Local synthesis of complement component C3 regulates acute renal transplant rejection","volume":"8","author":"Pratt","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2016.06.009_bib47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nri3225","article-title":"The role of complement in the early immune response to transplantation","volume":"12","author":"Sacks","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ekir.2016.06.009_bib48","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.drudis.2007.04.001","article-title":"Identifying and validating novel targets with in\u00a0vivo disease models: guidelines for study design","volume":"12","author":"Anders","year":"2007","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ekir.2016.06.009_bib49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ekir.2016.06.009_bib50","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.ki.5002103","article-title":"Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice","volume":"71","author":"Huugen","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2016.06.009_bib51","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1681\/ASN.2006070718","article-title":"Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies","volume":"17","author":"Schreiber","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib52","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1681\/ASN.2013101043","article-title":"With complements from ANCA mice","volume":"25","author":"Kettritz","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib54","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1681\/ASN.2005101116","article-title":"Therapeutic strategy\u00a0with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage","volume":"17","author":"Patel","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib55","doi-asserted-by":"crossref","first-page":"299ra121","DOI":"10.1126\/scitranslmed.aaa9853","article-title":"Results of a preclinical randomized controlled multicenter trial (pRCT): anti-CD49d treatment for acute brain ischemia","volume":"7","author":"Llovera","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ekir.2016.06.009_bib56","doi-asserted-by":"crossref","first-page":"e98856","DOI":"10.1371\/journal.pone.0098856","article-title":"The need for randomization in animal trials: an overview of systematic reviews","volume":"9","author":"Hirst","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2016.06.009_bib57","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ejphar.2015.03.026","article-title":"Translational value of animal models of kidney failure","volume":"759","author":"Ortiz","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ekir.2016.06.009_bib58","doi-asserted-by":"crossref","DOI":"10.3109\/08830185.2016.1154051","article-title":"Advances in pretransplant donor-specific antibody testing in solid organ transplantation: from bench to bedside","author":"Focosi","year":"2016","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.ekir.2016.06.009_bib59","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00012.2016","article-title":"Peritoneal dialysis: from bench to bedside and bedside to bench","author":"Perl","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ekir.2016.06.009_bib60","doi-asserted-by":"crossref","first-page":"988","DOI":"10.4049\/jimmunol.1103031","article-title":"Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis","volume":"189","author":"Berthier","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ekir.2016.06.009_bib61","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1021\/acs.jproteome.5b00814","article-title":"Preclinical alterations in the serum of COL(IV)A3(\u2013)\/(\u2013) mice as early biomarkers of Alport syndrome","volume":"14","author":"Muckova","year":"2015","journal-title":"J\u00a0Proteome Res"},{"issue":"suppl 4","key":"10.1016\/j.ekir.2016.06.009_bib62","doi-asserted-by":"crossref","first-page":"Siv124","DOI":"10.1093\/ndt\/gfu028","article-title":"Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies","volume":"29","author":"Gross","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2016.06.009_bib63","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ki.2011.407","article-title":"Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy","volume":"81","author":"Gross","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2016.06.009_bib64","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","article-title":"Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome","volume":"63","author":"Gross","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2016.06.009_bib65","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2016.06.009_bib66","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2016.06.009_bib67","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1172\/JCI119764","article-title":"Susceptibility to anti-glomerular basement membrane disease and Goodpasture syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice","volume":"100","author":"Kalluri","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2016.06.009_bib68","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/path.1336","article-title":"The evolution of crescentic nephritis and alveolar haemorrhage following induction of autoimmunity to glomerular basement membrane in an experimental model of Goodpasture's disease","volume":"200","author":"Reynolds","year":"2003","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.ekir.2016.06.009_bib69","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1681\/ASN.2013090978","article-title":"Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN","volume":"25","author":"McAdoo","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib70","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ajt.13520","article-title":"Humanized mouse models for transplant immunology","volume":"16","author":"Kenney","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2016.06.009_bib71","doi-asserted-by":"crossref","first-page":"F1288","DOI":"10.1152\/ajprenal.00316.2013","article-title":"CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice","volume":"305","author":"Sullivan","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ekir.2016.06.009_bib72","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2016.06.009_bib73","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1097\/01.ASN.0000042343.03375.1B","article-title":"The next treatments of chronic kidney disease: if we find them, can we test them?","volume":"13","author":"Hostetter","year":"2002","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib74","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ackd.2012.01.009","article-title":"Randomized controlled trials in nephrology: state of the evidence and critiquing the evidence","volume":"19","author":"Samuels","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ekir.2016.06.009_bib75","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/pme.11.7","article-title":"The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?","volume":"8","author":"Lillie","year":"2011","journal-title":"Per Med"},{"key":"10.1016\/j.ekir.2016.06.009_bib76","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0272-6386(12)80752-9","article-title":"Thrombotic thrombocytopenic purpura: evidence that infusion rather than removal of plasma induces remission of the disease","volume":"21","author":"Ruggenenti","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2016.06.009_bib77","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2215\/CJN.04950610","article-title":"Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility","volume":"6","author":"Perico","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib78","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000381480","article-title":"A\u00a0multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study","volume":"130","author":"Daina","year":"2015","journal-title":"Nephron"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2016.06.009_bib79","doi-asserted-by":"crossref","first-page":"Si31","DOI":"10.1093\/ndt\/gfv035","article-title":"Twenty-five years of RENHIS: a history of histopathological studies within EUVAS","volume":"30","author":"van Daalen","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2016.06.009_bib80","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2016.06.009_bib81","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib82","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1681\/ASN.2013111155","article-title":"Heterogeneous genetic alterations in sporadic nephrotic syndrome associate with resistance to immunosuppression","volume":"26","author":"Giglio","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib83","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ekir.2016.06.009_bib84","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2015070763","article-title":"Race, APOL1 risk, and eGFR decline in the general population","author":"Grams","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2016.06.009_bib85","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1211\/0022357991776831","article-title":"Enterohepatic circulation model for population pharmacokinetic analysis","volume":"51","author":"Funaki","year":"1999","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.ekir.2016.06.009_bib86","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/1756-185X.12212","article-title":"Overview of lupus nephritis management guidelines and perspective from Asia","volume":"16","author":"Mok","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ekir.2016.06.009_bib87","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group","volume":"343","author":"Chan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2016.06.009_bib88","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2016.06.009_bib89","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2016.06.009_bib90","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.2015.318","article-title":"Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis","volume":"89","author":"Rathi","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2016.06.009_bib91","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38790","article-title":"Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study","volume":"66","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2016.06.009_bib92","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational\u00a0single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2016.06.009_bib93","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/0961203308100481","article-title":"European consensus statement on the terminology used in the management of lupus glomerulonephritis","volume":"18","author":"Gordon","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2016.06.009_bib94","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2016.06.009_bib95","doi-asserted-by":"crossref","first-page":"e000123","DOI":"10.1136\/lupus-2015-000123","article-title":"A\u00a0proteinuria cut-off level of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ekir.2016.06.009_bib96","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000045998","article-title":"Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion","volume":"88","author":"Ruggenenti","year":"2001","journal-title":"Nephron"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024916300481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024916300481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:20:20Z","timestamp":1762831220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024916300481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S2468024916300481"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2016.06.009","relation":{},"ISSN":["2468-0249"],"issn-type":[{"type":"print","value":"2468-0249"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease\u2014The Berlin Roadmap","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2016.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016, International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}